A5024695327- Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Chronic Lymphocytic Leukemia Research
- Protein Degradation and Inhibitors
- Angiogenesis and VEGF in Cancer
- Neuroblastoma Research and Treatments
- Multiple Myeloma Research and Treatments
- Sarcoma Diagnosis and Treatment
- Ocular Oncology and Treatments
- SARS-CoV-2 and COVID-19 Research
- Acute Lymphoblastic Leukemia research
- Childhood Cancer Survivors' Quality of Life
- CAR-T cell therapy research
- Renal Transplantation Outcomes and Treatments
- Ubiquitin and proteasome pathways
- Vascular Tumors and Angiosarcomas
- Glioma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Complement system in diseases
- Cutaneous lymphoproliferative disorders research
- CNS Lymphoma Diagnosis and Treatment
- Soft tissue tumor case studies
- Epigenetics and DNA Methylation
- Tumors and Oncological Cases
Universitätsmedizin Rostock
2024
Universitätsklinikum des Saarlandes
2022
Hospital Clínic de Barcelona
2009-2018
Universitat de Barcelona
2005-2014
Hospital Sant Joan de Déu Barcelona
2004-2014
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2011-2013
MYC alterations influence the survival of patients with diffuse large B-cell lymphoma. Most studies have focused on translocations but there is little information regarding impact numerical and protein expression. We analyzed genetic expression MYC, BCL2, BCL6, MALT1 in 219 cases rearrangement occurred as sole abnormality (MYC single-hit) 3% cases, concurrent BCL2 and/or BCL6 rearrangements double/triple-hit) 4%, amplifications 2% gains 19%. single-hit, double/triple-hit amplifications, not...
Background Diffuse large B-cell lymphoma is a clinically and molecularly heterogeneous disease. Gene expression profiling studies have shown that the tumor microenvironment affects survival angiogenesis-related signature prognostically unfavorable. The contribution of histopathological microvessel density to in diffuse lymphomas treated with immunochemotherapy remains unknown. purpose this study assess prognostic impact two independent series patients immunochemotherapy.Design Methods One...
Constitutive activation of the chemokine receptor CXCR4 has been associated with tumor progression, invasion, and chemotherapy resistance in different cancer subtypes. Although pathway recently suggested as an adverse prognostic marker diffuse large B-cell lymphoma, its biological relevance this disease remains underexplored. In a homogeneous set 52 biopsies from patients, antibody-based cytokine array showed that tissue levels CXCL12 correlated high microvessel density bone marrow...
Abstract Primary congenital cervical neuroblastomas are very rare. A history of upper aerodigestive compromise with Horner syndrome can be value for the early diagnosis this lesion. Congenital usually have a favorable outcome. Like all other clinically relevant groups neuroblastomas, management should take into consideration biological findings each tumor, which predicts outcome than clinical findings. Pediatr Blood Cancer 2004;43:785–787. © 2004 Wiley‐Liss, Inc.
Abstract Opsoclonus‐myoclonus‐ataxia (OMA) secondary to Epstein‐Barr virus (EBV) infection has only been described in three pediatric patients. Previous reports suggested that evidence for a recent EBV the absence of an occult neoplasm would predict favorable prognosis OMA as well no tumor development. We present case 20‐month‐old child with associated microbiologically documented acute and thoracic ganglioneuroblastoma diagnosed 5 months later. Pediatr Blood Cancer. © 2005 Wiley‐Liss, Inc.
Infantile fibrosarcoma (IFS) is a rare pediatric tumor of intermediate malignancy with high local aggressiveness that typically presents in young infants. Its occurrence the head and neck region rare. Complete non-mutilating surgical resection often not possible, requiring multimodal treatment. IFS frequently harbors neurotrophic receptor tyrosine kinase (NTRK) fusions. Targeted therapy NTRK inhibitors modifying treatment paradigms IFS.
We report the case of a Jehovah's Witness adolescent patient with immune-mediated thrombotic thrombocytopenic purpura after SARS-Cov2 infection successfully treated without therapeutic plasma exchange (TPE) using caplacizumab, corticosteroids, rituximab, and extracorporeal immunoadsorption (EIA). Further patients for whom TPE is not an option might benefit from this approach.
Abstract Constitutive activation of CXCR4, a chemokine receptor commonly overexpressed in cancer, is associated with tumor progression, invasion, and chemotherapy resistance. Although the CXCR4 pathway has recently been suggested as an adverse prognostic marker diffuse large B-cell lymphoma (DLBCL), its biological relevance remains underexplored evolution malignant clone traditionally thought to rely mainly on microenvironment-independent factors, including MYC. To evaluate possible...